Neurotrope Inc (NASDAQ:NTRP) has received a consensus broker rating score of 2.00 (Buy) from the two analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company. Neurotrope’s rating score has declined by 100% in the last 90 days as a result of a number of analysts’ upgrades and downgrades.

Analysts have set a 12-month consensus target price of $8.50 for the company and are anticipating that the company will post ($0.32) earnings per share for the current quarter, according to Zacks. Zacks has also given Neurotrope an industry rank of 76 out of 256 based on the ratings given to related companies.

Several equities research analysts have recently weighed in on the company. Maxim Group cut Neurotrope from a “buy” rating to a “hold” rating in a research report on Monday. Zacks Investment Research upgraded Neurotrope from a “hold” rating to a “buy” rating and set a $6.50 target price for the company in a research note on Wednesday, August 21st. Janney Montgomery Scott lowered Neurotrope from a “buy” rating to a “neutral” rating and cut their target price for the company from $13.00 to $1.00 in a research note on Wednesday. Finally, ValuEngine upgraded Neurotrope from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Morgan Stanley raised its stake in shares of Neurotrope by 46.7% in the second quarter. Morgan Stanley now owns 20,402 shares of the company’s stock valued at $164,000 after purchasing an additional 6,490 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Neurotrope by 21.7% in the second quarter. Vanguard Group Inc. now owns 266,735 shares of the company’s stock valued at $2,139,000 after purchasing an additional 47,609 shares in the last quarter. BlackRock Inc. raised its stake in shares of Neurotrope by 144.3% in the second quarter. BlackRock Inc. now owns 60,041 shares of the company’s stock valued at $482,000 after purchasing an additional 35,464 shares in the last quarter. NorthRock Partners LLC raised its stake in shares of Neurotrope by 45.5% in the second quarter. NorthRock Partners LLC now owns 104,000 shares of the company’s stock valued at $834,000 after purchasing an additional 32,500 shares in the last quarter. Finally, Cannell Peter B & Co. Inc. raised its stake in shares of Neurotrope by 7.5% in the second quarter. Cannell Peter B & Co. Inc. now owns 229,481 shares of the company’s stock valued at $1,840,000 after purchasing an additional 16,100 shares in the last quarter. Institutional investors and hedge funds own 15.00% of the company’s stock.

Shares of NTRP traded down $0.07 during mid-day trading on Monday, hitting $0.83. The company’s stock had a trading volume of 5,242 shares, compared to its average volume of 132,961. Neurotrope has a one year low of $0.81 and a one year high of $9.38. The firm has a market capitalization of $13.02 million, a PE ratio of -0.62 and a beta of 2.41. The stock’s 50-day moving average is $5.08 and its two-hundred day moving average is $5.91.

About Neurotrope

Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases.

Read More: How to calculate compound interest

Get a free copy of the Zacks research report on Neurotrope (NTRP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.